These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3717938)

  • 1. Aztreonam treatment of gram-negative septicemia.
    Pierard D; Boelaert J; Van Landuyt HW; Naessens A; Huyghens L; Lauwers S
    Antimicrob Agents Chemother; 1986 Feb; 29(2):359-61. PubMed ID: 3717938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empiric antimicrobial therapy with aztreonam or ceftazidime in gram-negative septicemia.
    Lagast H; Klastersky J; Kains JP; van der Auwera P; Meunier F; Woussen F; Thijs JP
    Am J Med; 1986 May; 80(5C):79-84. PubMed ID: 3521272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of low-dose aztreonam in the treatment of moderate to severe infections due to gram-negative bacilli.
    Clergeot A; Steru D; Rosset MA; Carbon C
    Rev Infect Dis; 1991; 13 Suppl 7():S648-51. PubMed ID: 2068476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aztreonam in the treatment of serious gram-negative infections in the elderly.
    Deger F; Douchamps J; Freschi E; Thys JP; Nève P; Herchuelz A
    Int J Clin Pharmacol Ther Toxicol; 1988 Jan; 26(1):22-6. PubMed ID: 3403089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative clinical evaluation of aztreonam versus aminoglycosides in gram-negative septicaemia.
    Gudiol F; Pallarés R; Ariza X; Fernández-Viladrich P; Rufi G; Liñares J
    J Antimicrob Chemother; 1986 May; 17(5):661-71. PubMed ID: 3722035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections.
    LeFrock JL; Smith BR; Chandrasekar P; Rolston KV; Molavi A; Kannangara W
    Arch Intern Med; 1987 Feb; 147(2):325-8. PubMed ID: 3813751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections.
    Henry SA; Bendush CB
    Am J Med; 1985 Feb; 78(2A):57-64. PubMed ID: 3881950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of aztreonam therapy for serious infections due to gram-negative bacteria.
    McKellar PP
    Rev Infect Dis; 1985; 7 Suppl 4():S803-9. PubMed ID: 3909340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of aztreonam in serious gram-negative infections.
    Smith G; Bunney RG; Farrell ID; Wood MJ
    J Antimicrob Chemother; 1988 Feb; 21(2):233-41. PubMed ID: 3283094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful response of severe neonatal gram-negative infection to treatment with aztreonam.
    Constantopoulos A; Thomaidou L; Loupa H; Papoulias G
    Chemotherapy; 1989; 35 Suppl 1():101-5. PubMed ID: 2731446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with aztreonam in the treatment of gram-negative bacteremia.
    Scully BE; Henry SA
    Rev Infect Dis; 1985; 7 Suppl 4():S789-93. PubMed ID: 3909338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients.
    Rabinad E; Bosch-Perez A
    Chemotherapy; 1989; 35 Suppl 1():1-7. PubMed ID: 2659288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections.
    Naber KG; Dette GA; Kees F; Knothe H; Grobecker H
    J Antimicrob Chemother; 1986 Apr; 17(4):517-27. PubMed ID: 3710959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with aztreonam in Europe: a summary of studies in Belgium, England, Finland, Ireland, the Netherlands, Norway, Portugal, and Sweden.
    Norrby SR
    Rev Infect Dis; 1985; 7 Suppl 4():S836-9. PubMed ID: 2934788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients.
    Ariza J; Xiol X; Esteve M; Fernández Bañeres F; Liñares J; Alonso T; Gudiol F
    Hepatology; 1991 Jul; 14(1):91-8. PubMed ID: 2066075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aztreonam therapy for serious gram-negative infections in children.
    Stutman HR; Chartrand SA; Tolentino T; Friedhoff L; Marks MI
    Am J Dis Child; 1986 Nov; 140(11):1147-51. PubMed ID: 3766490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical efficacy of aztreonam in refractory infections in children].
    Ogura H; Hamada F; Fujieda M; Matsumoto K; Araki K; Ogura Y; Kuramitsu M; Kurashige T; Kitamura I
    Jpn J Antibiot; 1985 Nov; 38(11):3349-57. PubMed ID: 4094068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of low dose aztreonam in the treatment of moderate to severe gram-negative bacterial infections.
    Clergeot A; Steru D; Rosset MA; Carbon C
    J Antimicrob Chemother; 1989 May; 23(5):753-8. PubMed ID: 2759924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of serious gram-negative infections with aztreonam.
    Greenberg RN; Reilly PM; Luppen KL; McMillian R; Bollinger M; Wolk SM; Darji TB; Noorani AA
    J Infect Dis; 1984 Nov; 150(5):623-30. PubMed ID: 6541672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined aztreonam and gentamicin therapy for pseudomonal lower respiratory tract infections.
    Andrews R; Fasoli R; Scoggins WG; Algozzine GJ; Spann RW; Sundaresh KV; Mathers JA; Babb R; Kuppinger M; Cooper B
    Clin Ther; 1994; 16(2):236-52. PubMed ID: 8062319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.